Back to Search
Start Over
Cannabidiol as an Adjunctive Treatment for Schizophrenia.
- Source :
-
Psychiatric Times . Apr2019, Vol. 36 Issue 4, preceding p5-7. 4p. - Publication Year :
- 2019
-
Abstract
- The article explores the potential of cannabidiol (CBD) as an adjunctive treatment for schizophrenia. Topics covered include the approval by the U.S. Food and Drug Administation of Epidiolex as the first cannabis plant-derived medication for the treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome, the association between cannabis use and psychosis, and studies on the use of CBD to treat psychosis in individuals with schizophrenia or non-affective psychosis.
- Subjects :
- *DRUG therapy for convulsions
*SCHIZOPHRENIA risk factors
*PSYCHOSES
*CLINICAL trials
*DOSE-response relationship in biochemistry
*DRUG labeling
*DRUGS of abuse
*LENNOX-Gastaut syndrome
*SPASMS
*MEDICAL marijuana
*AT-risk people
*PHYSICIANS' attitudes
*DRAVET syndrome
*DRUG administration
*DRUG dosage
*PREVENTION
DRUG therapy for schizophrenia
Subjects
Details
- Language :
- English
- ISSN :
- 08932905
- Volume :
- 36
- Issue :
- 4
- Database :
- Academic Search Index
- Journal :
- Psychiatric Times
- Publication Type :
- Academic Journal
- Accession number :
- 135948636